Süsal C, Roelen D L, Fischer G, Campos E F, Gerbase-DeLima M, Hönger G, Schaub S, Lachmann N, Martorell J, Claas F
Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, Heidelberg, Germany.
Tissue Antigens. 2013 Aug;82(2):83-92. doi: 10.1111/tan.12137. Epub 2013 May 30.
One of the major tasks of human leukocyte antigen (HLA) laboratories is the pretransplant determination of unacceptable HLA antigen mismatches (UAM) in organ transplant recipients. HLA antigen specificities are determined against which the patient has circulating alloantibodies that are expected to harm the transplanted organ. Using the information on UAM, negative crossmatch (XM) prediction or 'virtual XM' is possible when a potential donor's complete HLA typing is available. Before the introduction of solid-phase antibody detection assays, UAM were determined using the complement-dependent cytotoxicity methodology. After the introduction of the single antigen bead technique, however, various UAM determination algorithms have emerged. In this report, six different laboratories worldwide present how they determine UAM in their collective of kidney transplant recipients in the pretransplant phase and proceed thereafter to transplantation.
人类白细胞抗原(HLA)实验室的主要任务之一是在器官移植受者移植前确定不可接受的HLA抗原错配(UAM)。要确定患者体内循环的同种异体抗体所针对的HLA抗原特异性,这些抗体预计会损害移植器官。当有潜在供体的完整HLA分型信息时,利用UAM信息可以进行阴性交叉配型(XM)预测或“虚拟XM”。在固相抗体检测方法引入之前,UAM是使用补体依赖细胞毒性方法来确定的。然而,在单抗原珠技术引入之后,出现了各种UAM确定算法。在本报告中,全球六个不同的实验室介绍了他们如何在肾移植受者群体的移植前阶段确定UAM,并在此之后进行移植。